Board of the Pension Protection Fund Invests $418,000 in Insulet Co. (NASDAQ:PODD)

Board of the Pension Protection Fund bought a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,600 shares of the medical instruments supplier’s stock, valued at approximately $418,000.

Other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. raised its holdings in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after purchasing an additional 389,639 shares during the last quarter. Geode Capital Management LLC grew its position in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Clearbridge Investments LLC grew its position in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after purchasing an additional 75,526 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares in the last quarter.

Insulet Trading Down 0.4 %

Shares of PODD stock opened at $267.04 on Wednesday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.77. The company has a market capitalization of $18.73 billion, a PE ratio of 45.73, a price-to-earnings-growth ratio of 4.12 and a beta of 1.22. The firm has a 50 day moving average price of $264.57 and a two-hundred day moving average price of $230.93. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Piper Sandler raised their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Wells Fargo & Company upped their price target on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, TD Cowen lifted their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.